Instituto de Medicina Regenerativa
11
1
1
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
72.7%
8 terminated/withdrawn out of 11 trials
11.1%
-75.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Pilot Study of Neoantigen Peptides for the Treatment of Neoplasms
Role: lead
Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19
Role: lead
Pilot Study of Neoantigen Peptides and Leukine for the Treatment of Neoplasms
Role: lead
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stem Cells in Patients With Frailty Syndrome
Role: collaborator
Safety and Efficacy of Adipose Derived Stem Cells for Congestive Heart Failure
Role: collaborator
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients After Stroke
Role: collaborator
Study to Assess the Safety and Cardiovascular Effects of Autologous Adipose-Derived Stromal Cells Implantation In Patients During the Acute Recovery Phase of ST-Elevation Myocardial Infarction
Role: collaborator
Safety and Efficacy of Adipose Derived Stem Cells for Non-Ischemic Congestive Heart Failure
Role: collaborator
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Renal Failure
Role: collaborator
Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Diffuse Lesions in the Brain
Role: collaborator
Adipose Derived Stem Cell Therapy for Autism
Role: collaborator
All 11 trials loaded